IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 67,473 shares of the medical research company’s stock after acquiring an additional 1,273 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in IQVIA were worth $13,259,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC increased its position in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. Cantillon Capital Management LLC lifted its holdings in shares of IQVIA by 12.3% in the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after buying an additional 226,017 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Impax Asset Management Group plc grew its holdings in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares during the period. Finally, Nordea Investment Management AB raised its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IQV. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Citigroup lowered their price target on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday. Finally, Robert W. Baird reduced their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

IQVIA stock opened at $183.75 on Wednesday. The firm’s 50-day moving average is $198.52 and its two-hundred day moving average is $213.86. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market capitalization of $32.36 billion, a P/E ratio of 24.50, a P/E/G ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.